NCT05017662View on ClinicalTrials.gov

A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 14, 2021

Primary Completion Date

April 29, 2025

Study Completion Date

April 29, 2025

Conditions
Neuroendocrine Tumors
Interventions
OTHER

Data collection

Participants will have surveillance visits every 3 months up to 5 years after their first dose of 177Lu-IPN01072 in Study OPS-C-001.

Trial Locations (7)

1090

Medical University of Vienna, Vienna

3002

Peter Maccallum Cancer Center, Melbourne

4031

University Hospital Basel, Basel

6009

Ramsay Hollywood Private Hospital, Perth

8200

Aarhus University Hospital, Aarhus

44093 Cedex 1

Hôtel Dieu de Nantes, Nantes

NW3 2QG

Royal Free Hospital London, London

Sponsors
All Listed Sponsors
lead

Ariceum Therapeutics GmbH

INDUSTRY

NCT05017662 - A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072 | Biotech Hunter | Biotech Hunter